The Medicines and Healthcare products Regulatory Agency (MHRA) has introduced temporary safety measures for Esmya (ulipristal acetate) while an EU-wide review investigates the link between the medicine and serious liver injury, including four cases that required liver transplantation.1 Clinicians should not initiate or re-start treatment and should monitor liver function in current and recent users.

Esmya is licensed for use in adult women of reproductive age for pre-operative treatment and for intermittent treatment of moderate to severe symptoms of …